Oxcarbazepine (All indications) updated on 04-22-2025

Learning disorders

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19373
R82191		 Straub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 Learning difficulty - ICD-10 codes: F81.0, F81.2, F81.8x, R48.0 - Mean follow up (full cohort): 3.4 years during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes 0.98 [0.29;3.38] -/660   43/8,887 - 660
ref
S9092
R31148		 Elkjaer (Oxcarbazepine), 2018 Mathematics at 6th grade during pregnancy (anytime or not specified) population based cohort propective unexposed (general population or NOS) Adjustment: Yes extrapolated (cont. endpoint) 1.06 [1.00;1.11] -/124   -/241,647 - 124
ref
Total 2 studies 1.06 [1.01;1.12] 0 784
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Straub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026Straub, 2026 1 0.98[0.29; 3.38]-6600%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Elkjaer (Oxcarbazepine), 2018Elkjaer, 2018 2 1.06[1.00; 1.11]-124100%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.06[1.01; 1.12]-7840.25.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick) (Oxcarbazepine) (Epilepsy; 2: Oxcarbazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.06[1.01; 1.12]-7840%NAStraub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 Elkjaer (Oxcarbazepine), 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.06[1.01; 1.12]-124 -NAElkjaer (Oxcarbazepine), 2018 1 unexposed, sickunexposed, sick 0.98[0.29; 3.35]-660 -NAStraub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 1 Tags Adjustment   - Yes  - Yes 1.06[1.01; 1.12]-7840%NAStraub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 Elkjaer (Oxcarbazepine), 2018 2 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 1.06[1.01; 1.12]-124 -NAElkjaer (Oxcarbazepine), 2018 1 All studiesAll studies 1.06[1.01; 1.12]-7840%NAStraub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 Elkjaer (Oxcarbazepine), 2018 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.06[1.01; 1.12]-124 -NAElkjaer (Oxcarbazepine), 2018 1 unexposed, sick controlsunexposed, sick controls 0.98[0.29; 3.35]34660 -NAStraub (Controls unexposed, sick) (Oxcarbazepine) (Epilepsy), 2026 10.510.01.0